인쇄하기
취소

SK acquires approval of first ‘Vimpat’ generic, next-generation epilepsy therapy

Published: 2016-09-05 15:52:04
Updated: 2016-09-05 15:52:04

SK Chemicals acquired a permit to commercialize the first generic of ‘Vimpat Tab(lacosamide)’ that is known as a next-generation epilepsy therapy.

According to the industry on the 1st, SK Chemicals acquired approval of ‘Vimsk Tab,’ a Vimpat’s generic drug, on the 31st for the first time in Korea.

Vimpat, a product launched by Korea UBC on December 2011, is used as an addition therapy to treat...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.